Systemic Inflammation and Outcome in 2295 Patients with Stage I –III Colorectal Cancer from Scotland and Norway: First Results from the ScotScan Colorectal Cancer Group
ConclusionsThe SIR differs between populations from different countries; however prognostic value remains similar. The present study strongly supports the routine reporting of the mGPS in patients with CRC.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Eloxatin | Norway Health | Scotland Health | Study | Xeloda